Embera is developing the first medication that treats addiction by moderating activity in the stress response system.

EMB-001 may potentially reduce the cravings and loss of control that drive addiction by uniquely targeting multiple pathways, to maximize potential efficacy more than either drug used alone. A therapy that breaks these barriers and results in long term abstinence and recovery would be a significant contribution to the treatment of a broad range of addictions.

Media & Publications

,

New approach to drug development could give rise to cocaine treatment

/
Researchers and a specialty pharmaceutical company have taken a longstanding theory about addiction and have used it to develop a novel approach to its treatment with medication, in the hope of creating the breakthrough drug for patients with cocaine dependence.
,

Embera NeuroTherapeutics Announces Positive Topline Data from Phase 1b Cocaine Interaction Study of EMB-001

/
Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for cocaine, nicotine, and other addictions, today announced that EMB-001 was found to be well-tolerated in a Phase 1b cocaine interaction study, and no new safety signals were observed.
,

New Stress Response Modulation Drug Showing Promise in the Treatment of Addiction

/
Robert Linke, Embera’s president and CEO, spoke with CEOCFO Magazine regarding Embera’s new approach to treating addictions and how attitudes toward addiction are evolving.